

## Reflex Mismatch Repair (MMR) Immunohistochemistry for New Diagnosis of Rectal Cancer

Effective Date: March 11<sup>th</sup>, 2024

A recent study of MMR-deficient rectal adenocarcinoma patients demonstrated dramatic clinical responses to neoadjuvant dostarlimab treatment, with all study patients experiencing complete clinical responses to dostarlimab, obviating the need for surgery (N Eng J Med 2022;386:2363-76.) (PMID 35660797). Therefore, the precision medicine subcommittee of the oncology committee, as well as the oncology practice group at Corewell Health East have unanimously recommended that reflex MMR immunohistochemistry be performed on all newly diagnosed cases of rectal adenocarcinoma to determine eligibility for neoadjuvant immunotherapy, with the potential for tremendous clinical benefit. Similar to other reflex tests, MMR immunohistochemistry will be ordered by the signing pathologist when the biopsy report is finalized. This change does not impact test codes.

### Current Indications for Reflex MMR Immunohistochemistry:

Metastatic carcinoma – Any (excluding regional lymph nodes)  
Colon carcinoma – Resection  
Endometrial carcinoma – Resection

### New Indications for Reflex MMR Immunohistochemistry:

Rectal or rectosigmoid carcinoma – Biopsy (new diagnosis, including cases suspicious for invasion)

**CPT Codes (Technical):** 88341x3, 88342

If you have questions, please contact please contact your Beaumont Laboratory Customer Service Department:

- Farmington Hills, Grosse Pointe, Royal Oak and Troy: 800-551-0488 or 248-551-1155, Option 5
- Dearborn, Taylor, Trenton and Wayne: 800-245-3725, Option 1

Laboratory Test Directory: <http://beaumontlaboratory.com/test-lab-directory>.

---

**Date submitted:** November 28, 2023

**Submitted by:** John D. Schwartz, M.D., Medical Director, Molecular Pathology